Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Bookmark and Share
Published: 30 May 2015
Views: 1547
Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada

Prof Margolese presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

Read the news article and watch the interview for more.